Evidence map›Paper›PMID 35091437›Full record

ArticleBMJ open respiratory research2022

Application of liquid biopsy-based targeted capture sequencing analysis to improve the precision treatment of non-small cell lung cancer by tyrosine kinase inhibitors.

Lei Zhang, John Coffin, Kim Formenti, Quincy Chu, Iyare Izevbaye

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open respiratory research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 57% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Lei ZhangDepartment of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada.
John CoffinDepartment of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada.
Kim FormentiDepartment of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada.
Quincy ChuCross Cancer Institute, Alberta Health Services, Edmonton, Alberta, Canada.
Iyare IzevbayeDepartment of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada izevbaye@ualberta.ca.
University of Alberta · CAAlberta Health Services · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTargeted therapy of patients with non-small cell lung cancer (NSCLC) who harbour sensitising mutations by tyrosine kinase inhibitors (TKIs) has been found more effective than traditional chemotherapies. However, target genes status (eg, epidermal growth factor receptor (

methodsPlasma samples from patients with NSCLC who showed resistance to the first/second-generation

resultsA total of 24 plasma cell-free DNA (cfDNA) samples were tested by the targeted capture sequencing assay. 33.3% (8/24) cfDNA samples were positive for

conclusionThe targeted capture sequencing test can support comprehensive molecular analysis needed for TKIs treatment, which is promising to be clinically applied for the improved precision treatment of NSCLC.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsDrug Resistance, NeoplasmErbB ReceptorsHumansLiquid BiopsyMutationProtein Kinase InhibitorsErbB ReceptorsProtein Kinase Inhibitorsdrug reactionslung cancernon-small cell lung cancer

Identifiers

PMID35091437
PMCPMC8804681
OpenAlexW4210302595

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.